
    
      The primary objectives of the study are to evaluate and characterize the tolerability and
      safety profile of repeated doses of BAY1834942, and to characterize the pharmacokinetics of
      BAY1834942 after single dose.

      Secondary objectives are to evaluate the tumor response profile, pharmacodynamics,
      pharmacokinetics and immunogenicity after multiple doses of the drug.
    
  